Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$6.22 USD

6.22
1,161,700

-0.30 (-4.60%)

Updated Jul 2, 2024 04:00 PM ET

After-Market: $6.23 +0.01 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (104 out of 249)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4

Ironwood Pharmaceuticals (IRWD) reports higher-than-expected earnings and revenues in the fourth quarter.

What's in Store for Ironwood (IRWD) This Earnings Season?

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 Reasons Why Ironwood Stock Should Be in Your Portfolio

We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.

MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%

MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice

Does Ironwood Pharmaceuticals (IRWD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%

Marinus Pharmaceuticals (MRNS) shares rose nearly 8% in the last trading session, amid huge volumes.

Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year?

Is (IRWD) Outperforming Other Medical Stocks This Year?

Moving Average Crossover Alert: Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Pacira's Late-Stage Study on Exparel Label Expansion Positive

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

Top Ranked Momentum Stocks to Buy for December 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

Catalyst Focuses on Firdapse Label Expansion Amid Competition

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

Nalak Das headshot

5 Best-Performing, Top-Ranked Growth Stocks of November

Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

Sweta Killa headshot

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth quarter.

Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%

Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

FibroGen (FGEN) Soars: Stock Adds 9.6% in Session

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Ironwood Pharmaceuticals, Inc. (IRWD).

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.